Humana exec tapped for Walmart’s health, wellness division

Sean Slovenski, a former executive at Humana has been hired to run Walmart’s healthcare business, Bloomberg reportedHe most recently worked for digital health company Healthways. Slovenski has been named as senior vice president of heath and wellness for Walmart, effective August 1.

The appointment comes just months after reports surfaced Walmart may be in talks to acquire health insurance giant Humana. Walmart, like other retail providers including Amazon, has been increasingly looking for ways to expand into the healthcare sector.

Walmart and Humana already work together on drug plans for Medicare beneficiaries, according to Bloomberg, with some plans offering prescriptions for as little as $1 when customers pick up their drugs at Walmart or Sam’s Club.

“Because of its strategic importance, we’ve decided to put more focus on our Health & Wellness business in the near term,” Foran wrote in the memo.

In his new role, Slovenski will report directly to Greg Foran, who runs Walmart’s U.S. business, according to an internal memo dated July 12. He most recently served as president of the population health business at Healthways, which is part of digital health company Sharecare. Walmart has already teamed up with Sharecare for its employees to utilize the health monitoring resources.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Trimed Popup
Trimed Popup